NL300760I2 - Edoxaban, a salt thereof, a solvate thereof or an N-oxide thereof, in particular edoxaban tosylate - Google Patents
Edoxaban, a salt thereof, a solvate thereof or an N-oxide thereof, in particular edoxaban tosylateInfo
- Publication number
- NL300760I2 NL300760I2 NL300760C NL300760C NL300760I2 NL 300760 I2 NL300760 I2 NL 300760I2 NL 300760 C NL300760 C NL 300760C NL 300760 C NL300760 C NL 300760C NL 300760 I2 NL300760 I2 NL 300760I2
- Authority
- NL
- Netherlands
- Prior art keywords
- edoxaban
- solvate
- salt
- oxide
- tosylate
- Prior art date
Links
- HGVDHZBSSITLCT-JLJPHGGASA-N Edoxaban Chemical compound N([C@H]1CC[C@@H](C[C@H]1NC(=O)C=1SC=2CN(C)CCC=2N=1)C(=O)N(C)C)C(=O)C(=O)NC1=CC=C(Cl)C=N1 HGVDHZBSSITLCT-JLJPHGGASA-N 0.000 title 1
- 150000001204 N-oxides Chemical class 0.000 title 1
- 229960000622 edoxaban Drugs 0.000 title 1
- 229960005378 edoxaban tosylate Drugs 0.000 title 1
- ZLFZITWZOYXXAW-QXXZOGQOSA-N edoxaban tosylate Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1.N([C@H]1CC[C@@H](C[C@H]1NC(=O)C=1SC=2CN(C)CCC=2N=1)C(=O)N(C)C)C(=O)C(=O)NC1=CC=C(Cl)C=N1 ZLFZITWZOYXXAW-QXXZOGQOSA-N 0.000 title 1
- 150000003839 salts Chemical class 0.000 title 1
- 239000012453 solvate Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/429—Thiazoles condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
- C07D513/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06191—Dipeptides containing heteroatoms different from O, S, or N
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0827—Tripeptides containing heteroatoms different from O, S, or N
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2001187105 | 2001-06-20 | ||
JP2001243046 | 2001-08-09 | ||
JP2001311808 | 2001-10-09 | ||
JP2001398708 | 2001-12-28 | ||
PCT/JP2002/002683 WO2003000657A1 (fr) | 2001-06-20 | 2002-03-20 | Derives de diamine |
PCT/JP2002/006141 WO2003000680A1 (fr) | 2001-06-20 | 2002-06-20 | Derives de diamine |
Publications (1)
Publication Number | Publication Date |
---|---|
NL300760I2 true NL300760I2 (en) | 2017-07-20 |
Family
ID=27482359
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NL300760C NL300760I2 (en) | 2001-06-20 | 2015-09-29 | Edoxaban, a salt thereof, a solvate thereof or an N-oxide thereof, in particular edoxaban tosylate |
Country Status (12)
Country | Link |
---|---|
US (7) | US7365205B2 (enEXAMPLES) |
EP (1) | EP2343290A1 (enEXAMPLES) |
AR (1) | AR036102A1 (enEXAMPLES) |
BE (1) | BE2015C046I2 (enEXAMPLES) |
CY (2) | CY1113054T1 (enEXAMPLES) |
FR (1) | FR15C0068I2 (enEXAMPLES) |
MY (1) | MY153231A (enEXAMPLES) |
NL (1) | NL300760I2 (enEXAMPLES) |
PT (1) | PT1405852E (enEXAMPLES) |
TW (1) | TWI298066B (enEXAMPLES) |
WO (1) | WO2003000657A1 (enEXAMPLES) |
ZA (1) | ZA200309866B (enEXAMPLES) |
Families Citing this family (118)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI290136B (en) * | 2000-04-05 | 2007-11-21 | Daiichi Seiyaku Co | Ethylenediamine derivatives |
US7365205B2 (en) * | 2001-06-20 | 2008-04-29 | Daiichi Sankyo Company, Limited | Diamine derivatives |
PL220739B1 (pl) * | 2001-06-20 | 2015-12-31 | Daiichi Sankyo Company | Pochodne diaminy |
KR100908966B1 (ko) * | 2001-08-09 | 2009-07-22 | 다이이찌 세이야꾸 가부시기가이샤 | 디아민 유도체 |
JP4109288B2 (ja) * | 2002-12-25 | 2008-07-02 | 第一三共株式会社 | ジアミン誘導体 |
US7205318B2 (en) | 2003-03-18 | 2007-04-17 | Bristol-Myers Squibb Company | Lactam-containing cyclic diamines and derivatives as a factor Xa inhibitors |
US7378409B2 (en) | 2003-08-21 | 2008-05-27 | Bristol-Myers Squibb Company | Substituted cycloalkylamine derivatives as modulators of chemokine receptor activity |
EP1670739A4 (en) * | 2003-10-08 | 2007-08-08 | Bristol Myers Squibb Co | CYCLIC DIAMINES AND DERIVATIVES AS FACTOR XA INHIBITORS |
KR101215153B1 (ko) | 2003-11-12 | 2012-12-24 | 다이이찌 산쿄 가부시키가이샤 | 티아졸 유도체의 제조법 |
NZ548212A (en) * | 2003-12-29 | 2010-07-30 | Sepracor Inc | Pyrrole and pyrazole DAAO inhibitors |
TWI350168B (en) * | 2004-05-07 | 2011-10-11 | Incyte Corp | Amido compounds and their use as pharmaceuticals |
WO2006002350A1 (en) * | 2004-06-24 | 2006-01-05 | Incyte Corporation | Amido compounds and their use as pharmaceuticals |
WO2006012227A2 (en) * | 2004-06-24 | 2006-02-02 | Incyte Corporation | Amido compounds and their use as pharmaceuticals |
AU2005258248A1 (en) * | 2004-06-24 | 2006-01-05 | Incyte Corporation | Amido compounds and their use as pharmaceuticals |
CA2569507A1 (en) * | 2004-06-24 | 2006-02-02 | Incyte Corporation | Amido compounds and their use as pharmaceuticals |
US7687665B2 (en) * | 2004-06-24 | 2010-03-30 | Incyte Corporation | 2-methylprop anamides and their use as pharmaceuticals |
EA200700117A1 (ru) | 2004-06-24 | 2007-06-29 | Инсайт Корпорейшн | N-замещенные пиперидины и их применение в качестве фармацевтических препаратов |
TW200626156A (en) * | 2004-08-10 | 2006-08-01 | Incyte Corp | Amido compounds and their use as pharmaceuticals |
US7499687B2 (en) * | 2004-11-09 | 2009-03-03 | Theta Microelectronics, Inc. | Wireless transmitter DC offset recalibration |
US8110581B2 (en) * | 2004-11-10 | 2012-02-07 | Incyte Corporation | Lactam compounds and their use as pharmaceuticals |
KR20070097441A (ko) * | 2004-11-18 | 2007-10-04 | 인사이트 산 디에고 인코포레이티드 | 11-β 하이드록실 스테로이드 데하이드로게나제 유형 1의억제제 및 이를 사용하는 방법 |
MX2007009283A (es) * | 2005-02-18 | 2008-02-19 | Arpida Ag | Nuevos procesos para la preparacion de un benzofurano. |
WO2006106963A1 (ja) * | 2005-03-31 | 2006-10-12 | Daiichi Sankyo Company, Limited | トリアミン誘導体 |
WO2007006003A2 (en) | 2005-07-06 | 2007-01-11 | Sepracor Inc. | Combinations of eszopiclone and trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-n-methyl-1-napthalenamine or trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine, and methods of treatment of menopause and mood, anxiety, and cognitive disorders |
JPWO2007032371A1 (ja) | 2005-09-14 | 2009-03-19 | 大日本住友製薬株式会社 | 摂食調節剤としてのオキシインドール誘導体 |
CN101263110B (zh) * | 2005-09-16 | 2013-04-03 | 第一三共株式会社 | 旋光性的二胺衍生物及其制造方法 |
EP1931652A2 (en) * | 2005-09-21 | 2008-06-18 | Incyte Corporation | Amido compounds and their use as pharmaceuticals |
KR101415861B1 (ko) * | 2005-12-05 | 2014-07-04 | 인사이트 코포레이션 | 락탐 화합물 및 이를 사용하는 방법 |
CA2636275C (en) * | 2006-01-06 | 2013-02-12 | Sepracor Inc. | Tetralone-based monoamine reuptake inhibitors |
US20070203111A1 (en) | 2006-01-06 | 2007-08-30 | Sepracor Inc. | Cycloalkylamines as monoamine reuptake inhibitors |
WO2007084314A2 (en) * | 2006-01-12 | 2007-07-26 | Incyte Corporation | MODULATORS OF 11-ß HYDROXYL STEROID DEHYDROGENASE TYPE 1, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USING THE SAME |
EA200870216A1 (ru) * | 2006-01-31 | 2009-02-27 | Инсайт Корпорейшн | Амидо соединения и их применение в качестве лекарственных средств |
TW200808807A (en) * | 2006-03-02 | 2008-02-16 | Incyte Corp | Modulators of 11-β hydroxyl steroid dehydrogenase type 1, pharmaceutical compositions thereof, and methods of using the same |
WO2007103719A2 (en) * | 2006-03-03 | 2007-09-13 | Incyte Corporation | MODULATORS OF 11-β HYDROXYL STEROID DEHYDROGENASE TYPE 1, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USING THE SAME |
US8097760B2 (en) | 2006-03-31 | 2012-01-17 | Sunovion Pharmacuticals Inc. | Preparation of chiral amides and amines |
EP2013163A1 (en) * | 2006-05-01 | 2009-01-14 | Incyte Corporation | Tetrasubstituted ureas as modulators of 11-beta hydroxyl steroid dehydrogenase type 1 |
US7838544B2 (en) * | 2006-05-17 | 2010-11-23 | Incyte Corporation | Heterocyclic inhibitors of 11-β hydroxyl steroid dehydrogenase type 1 and methods of using the same |
US7579370B2 (en) * | 2006-06-30 | 2009-08-25 | Sepracor Inc. | Fused heterocycles |
US7884124B2 (en) * | 2006-06-30 | 2011-02-08 | Sepracor Inc. | Fluoro-substituted inhibitors of D-amino acid oxidase |
JP2009544616A (ja) * | 2006-07-21 | 2009-12-17 | 武田薬品工業株式会社 | アミド化合物 |
WO2008026563A1 (fr) | 2006-08-30 | 2008-03-06 | Shionogi & Co., Ltd. | Dérivé d'hydrazine amide |
ZA200904686B (en) * | 2007-01-18 | 2010-09-29 | Sepracor Inc | Inhibitiors of D-amino acid oxidase |
US7902252B2 (en) * | 2007-01-18 | 2011-03-08 | Sepracor, Inc. | Inhibitors of D-amino acid oxidase |
LT2140867T (lt) | 2007-03-29 | 2017-12-11 | Daiichi Sankyo Company, Limited | Farmacinė kompozicija |
NZ580429A (en) | 2007-05-31 | 2012-04-27 | Sepracor Inc | Phenyl substituted cycloalkylamines as monoamine reuptake inhibitors |
DE102007028406A1 (de) | 2007-06-20 | 2008-12-24 | Bayer Healthcare Ag | Substituierte Oxazolidinone und ihre Verwendung |
DE102007028319A1 (de) | 2007-06-20 | 2008-12-24 | Bayer Healthcare Ag | Substituierte Oxazolidinone und ihre Verwendung |
DE102007028407A1 (de) | 2007-06-20 | 2008-12-24 | Bayer Healthcare Ag | Substituierte Oxazolidinone und ihre Verwendung |
CL2008001839A1 (es) | 2007-06-21 | 2009-01-16 | Incyte Holdings Corp | Compuestos derivados de 2,7-diazaespirociclos, inhibidores de 11-beta hidroxil esteroide deshidrogenasa tipo 1; composicion farmaceutica que comprende a dichos compuestos; utiles para tratar la obesidad, diabetes, intolerancia a la glucosa, diabetes tipo ii, entre otras enfermedades. |
GB0721333D0 (en) * | 2007-10-31 | 2007-12-12 | Motac Neuroscience Ltd | Medicaments |
US20100120740A1 (en) * | 2008-08-07 | 2010-05-13 | Sepracor Inc. | Prodrugs of fused heterocyclic inhibitors of d-amino acid oxidase |
US9776963B2 (en) | 2008-11-10 | 2017-10-03 | The Trustees Of The University Of Pennsylvania | Small molecule CD4 mimetics and uses thereof |
JP5683273B2 (ja) | 2008-12-12 | 2015-03-11 | 第一三共株式会社 | 光学活性カルボン酸の製造方法 |
SI2371830T1 (sl) | 2008-12-17 | 2014-01-31 | Daiichi Sankyo Company, Limited | Postopek za pridobivanje diaminskih derivatov |
EP2383272A4 (en) | 2009-01-13 | 2012-07-25 | Daiichi Sankyo Co Ltd | ACTIVE BLOOD CREATION FACTOR HEMMER |
CN102348688B (zh) * | 2009-03-10 | 2014-07-09 | 第一三共株式会社 | 用于制备二胺衍生物的方法 |
ES2542237T3 (es) | 2009-03-13 | 2015-08-03 | Daiichi Sankyo Company, Limited | Procedimiento de producción de un derivado de diamina ópticamente activo |
WO2010131663A1 (ja) * | 2009-05-15 | 2010-11-18 | 第一三共株式会社 | オキサミド誘導体 |
SG176934A1 (en) | 2009-06-18 | 2012-01-30 | Daiichi Sankyo Co Ltd | Pharmaceutical composition having improved solubility |
FR2948372B1 (fr) | 2009-07-21 | 2011-07-22 | Servier Lab | Nouveaux derives chromeniques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
US20110034434A1 (en) * | 2009-08-07 | 2011-02-10 | Sepracor Inc. | Prodrugs of fused heterocyclic inhibitors of d-amino acid oxidase |
ES2706880T3 (es) * | 2010-02-22 | 2019-04-01 | Daiichi Sankyo Co Ltd | Preparación sólida de liberación sostenida para uso oral |
EP2540317A4 (en) | 2010-02-22 | 2014-04-16 | Daiichi Sankyo Co Ltd | SOLID PREPARATION WITH DELAYED RELEASE FOR ORAL ADMINISTRATION |
TW201200165A (en) | 2010-02-22 | 2012-01-01 | Daiichi Sankyo Co Ltd | Oral solid extended release dosage form |
WO2011115067A1 (ja) | 2010-03-19 | 2011-09-22 | 第一三共株式会社 | 抗凝固剤の溶出改善方法 |
JP5692873B2 (ja) | 2010-03-19 | 2015-04-01 | 第一三共株式会社 | ジアミン誘導体の結晶およびその製造方法 |
WO2011149110A1 (en) | 2010-05-28 | 2011-12-01 | Daiichi Sankyo Company, Limited | Novel composition for the prevention and/or treatment of thromboembolism |
ES2619374T3 (es) | 2010-07-02 | 2017-06-26 | Daiichi Sankyo Company, Limited | Procedimiento de preparación de sal derivada de diamina ópticamente activa |
HUP1000598A2 (en) | 2010-11-05 | 2012-09-28 | Richter Gedeon Nyrt | Indole derivatives |
CA2824885A1 (en) | 2011-01-19 | 2012-07-26 | Bayer Intellectual Property Gmbh | Binding proteins to inhibitors of coagulation factors |
ES2648164T3 (es) | 2011-07-08 | 2017-12-28 | Daiichi Sankyo Company, Limited | Procedimiento de control de calidad de productos |
EP2742941B1 (en) | 2011-08-10 | 2018-04-18 | Daiichi Sankyo Company, Limited | Pharmaceutical composition containing diamine derivative |
US20130158069A1 (en) | 2011-12-14 | 2013-06-20 | Daiichi Sankyo Company, Limited | Preventive and/or therapeutic agent for thromboembolism in thromboembolism patient with severe renal impairment |
CN102659757B (zh) * | 2012-04-24 | 2013-11-06 | 南京药石药物研发有限公司 | 一种合成5-氯-3-噻吩甲醛的中间体及其制备方法 |
EP2893928B1 (en) | 2012-09-03 | 2018-10-24 | Daiichi Sankyo Company, Limited | Hydromorphone hydrochloride-containing oral sustained-release pharmaceutical composition |
BR112015004666B1 (pt) | 2012-09-07 | 2022-04-26 | Novartis Ag | Derivados de indol carboxamida, seu uso, e composição farmacêutica |
WO2014081047A1 (en) | 2012-11-23 | 2014-05-30 | Daiichi Sankyo Company,Limited | Process for the preparation of (1s,4s,5s)-4-bromo-6-oxabicyclo[3.2.1] octan-7-one |
MY181020A (en) | 2013-03-15 | 2020-12-16 | Sanofi Sa | Heteroaryl compounds and uses thereof |
WO2014144737A1 (en) | 2013-03-15 | 2014-09-18 | Celgene Avilomics Research, Inc. | Heteroaryl compounds and uses thereof |
BR112015019669A2 (pt) * | 2013-03-29 | 2017-07-18 | Daiichi Sankyo Co Ltd | método de produção de um composto |
TWI602803B (zh) | 2013-03-29 | 2017-10-21 | 第一三共股份有限公司 | 光學活性二胺衍生物之製造方法 |
WO2015028919A1 (en) | 2013-08-29 | 2015-03-05 | Daiichi Sankyo Company, Limited | Agent for the treatment and prevention of cancer |
JP2017509622A (ja) | 2014-03-31 | 2017-04-06 | 第一三共株式会社 | 抗凝固薬として使用されるビタミンK拮抗薬に感受性を有する患者における、出血事象及び関連障害を治療及び予防するための第Xa因子阻害薬の使用 |
DE102014108210A1 (de) | 2014-06-11 | 2015-12-17 | Dietrich Gulba | Rodentizid |
WO2016025681A1 (en) | 2014-08-13 | 2016-02-18 | The Trustees Of The University Of Pennsylvania | Inhibitors of hiv-1 entry and methods of use thereof |
CN104529729B (zh) * | 2014-12-31 | 2016-03-30 | 浙江永太科技股份有限公司 | 一种2-氟-3-氯苯甲醛的制备方法 |
TWI571460B (zh) | 2016-03-14 | 2017-02-21 | 中化合成生技股份有限公司 | 二胺衍生物之製造方法 |
JP6831447B2 (ja) | 2016-07-13 | 2021-02-17 | マイラン ラボラトリーズ リミテッドMylan Laboratories Limited | アミン保護(1s,2r,4s)−1,2ーアミノ−n,n−ジメチルシクロヘキサン−4−カルボキサミドの塩 |
WO2018069769A1 (en) | 2016-10-13 | 2018-04-19 | Daiichi Sankyo Company, Limited | Pharmaceutical composition for inhibiting neointima formation of blood vessel |
US10301322B2 (en) | 2016-12-27 | 2019-05-28 | Apotex Inc. | Processes for the preparation of edoxaban and intermediates thereof |
WO2018165611A1 (en) * | 2017-03-10 | 2018-09-13 | Rutgers, The State University Of New Jersey | Indole derivatives as efflux pump inhibitors |
GB201807014D0 (en) | 2018-04-30 | 2018-06-13 | Univ Leeds Innovations Ltd | Factor xlla inhibitors |
TWI826474B (zh) | 2018-06-27 | 2023-12-21 | 日商第一三共股份有限公司 | 包含二胺衍生物之顆粒劑、以及其用途及製造方法 |
JP7558156B2 (ja) | 2018-09-26 | 2024-09-30 | ジエンス ヘンルイ メデイシンカンパニー リミテッド | エキサテカン類似体のリガンド-薬物コンジュゲート、その調製方法およびその適用 |
CA3114474A1 (en) | 2018-09-30 | 2020-04-02 | Jiangsu Hengrui Medicine Co., Ltd. | Anti-b7h3 antibody-exatecan analog conjugate and medicinal use thereof |
CN109942600B (zh) * | 2019-04-15 | 2021-08-20 | 内蒙古京东药业有限公司 | 一种依度沙班的制备方法 |
WO2021001728A1 (en) * | 2019-07-04 | 2021-01-07 | Glenmark Life Sciences Limited | Process for preparation of edoxaban |
EP3997075A1 (de) | 2019-07-10 | 2022-05-18 | Bayer Aktiengesellschaft | Verfahren zur herstellung von 2-(phenylimino)-1,3-thiazolidin-4-onen |
KR102333564B1 (ko) | 2019-11-28 | 2021-12-01 | 동방에프티엘(주) | 광학 활성 다이아민 유도체 및 티아졸 유도체의 생산을 위한 새로운 합성경로 |
TW202128227A (zh) | 2019-12-12 | 2021-08-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | 抗密蛋白抗體藥物偶聯物及其醫藥用途 |
JP2023510905A (ja) | 2020-01-22 | 2023-03-15 | 江蘇恒瑞医薬股▲ふん▼有限公司 | 抗trop-2抗体-エキサテカン類似体複合体及びその医薬用途 |
JP7730836B2 (ja) | 2020-03-25 | 2025-08-28 | 江蘇恒瑞医薬股▲ふん▼有限公司 | 抗体薬物複合体の調製方法 |
JP7689979B2 (ja) | 2020-03-25 | 2025-06-09 | 江蘇恒瑞医薬股▲ふん▼有限公司 | 抗体薬物複合体を含む医薬組成物及びその使用 |
WO2021190583A1 (zh) | 2020-03-25 | 2021-09-30 | 江苏恒瑞医药股份有限公司 | 抗psma抗体-依喜替康类似物偶联物及其医药用途 |
CA3186295A1 (en) | 2020-06-08 | 2021-12-16 | Baili-Bio (Chengdu) Pharmaceutical Co., Ltd. | Camptothecin drug having high-stability hydrophilic connecting unit and conjugate thereof |
WO2022129535A1 (en) | 2020-12-18 | 2022-06-23 | Krka, D.D., Novo Mesto | Edoxaban formulation containing no sugar alcohols |
KR20220087933A (ko) | 2020-12-18 | 2022-06-27 | 엠에프씨 주식회사 | 디아민 유도체의 제조방법 |
EP4070658A1 (de) | 2021-04-06 | 2022-10-12 | BIORoxx GmbH | Verwendung von blutgerinnungshemmenden verbindungen als rodentizide |
GB202107722D0 (en) | 2021-05-28 | 2021-07-14 | Lunac Therapeutics Ltd | Factor XIIA Inhibitors |
CA3237844A1 (en) | 2021-11-15 | 2023-05-19 | Systimmune, Inc. | Bispecific antibody-camptothecin drug conjugate and pharmaceutical use thereof |
CN116178251A (zh) * | 2021-11-26 | 2023-05-30 | 上海汇伦医药股份有限公司 | 一种依度沙班中间体的制备方法 |
MX2024006732A (es) | 2021-12-03 | 2024-07-22 | Systimmune Inc | Conjugado de anticuerpo anti-trop2 humano - fármaco de camptotecina y uso médico del mismo. |
CN114456194B (zh) * | 2021-12-14 | 2023-07-07 | 浙江九洲药业股份有限公司 | 甲苯磺酸艾多沙班的中间体及其制备方法 |
CN115583900A (zh) * | 2022-04-29 | 2023-01-10 | 张邦成都生物医药科技有限公司 | 一种高纯度依度沙班中间体的制备方法 |
WO2023223346A1 (en) | 2022-05-16 | 2023-11-23 | Mylan Laboratories Limited | An improved process for the preparation of edoxaban intermediate |
CN117752813A (zh) | 2022-09-26 | 2024-03-26 | 成都百利多特生物药业有限责任公司 | 抗cd33抗体和抗cd33抗体-药物偶联物及其用途 |
CN115724792A (zh) | 2022-11-24 | 2023-03-03 | 上海柏狮生物科技有限公司 | 一种依度沙班关键中间体及其合成方法 |
NL2036011B1 (en) | 2023-10-12 | 2025-04-30 | Synapse Res Institute | Molecules for reversing anti-coagulant activity of direct oral anticoagulants |
Family Cites Families (92)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3376269A (en) * | 1964-02-26 | 1968-04-02 | Monsanto Co | Polyamides containing adjacent heterocycle linkages |
JPS63500796A (ja) | 1985-06-07 | 1988-03-24 | ジ・アップジョン・カンパニ− | アミノシクロアルキルアミドの抗不整脈剤用途 |
WO1992004017A1 (en) * | 1990-09-10 | 1992-03-19 | The Upjohn Company | Cis-n-(2-aminocyclohexyl)benzamide and their enantiomers as anticonvulsants |
IL100576A (en) | 1991-01-18 | 1995-11-27 | Eli Lilley And Company | Cephalosporin antibiotics |
WO1993010022A1 (en) | 1991-11-14 | 1993-05-27 | Frutin Bernard D | A pressurised container |
US5430150A (en) * | 1992-12-16 | 1995-07-04 | American Cyanamid Company | Retroviral protease inhibitors |
JPH09503994A (ja) | 1993-03-03 | 1997-04-22 | イーライ・リリー・アンド・カンパニー | バラノイド |
NZ262768A (en) | 1993-03-17 | 1997-03-24 | Meiji Seika Co | Platelet aggregation inhibitors |
KR970001164B1 (ko) | 1993-06-09 | 1997-01-29 | 한국과학기술연구원 | 세팔로스포린계 항생제 및 그의 제조방법 |
CN1076345C (zh) | 1993-10-19 | 2001-12-19 | 住友制药株式会社 | 2,3-二氨基丙酸衍生物 |
TW270114B (enEXAMPLES) | 1993-10-22 | 1996-02-11 | Hoffmann La Roche | |
US5525042A (en) | 1993-11-08 | 1996-06-11 | Clearline Systems, Inc. | Liquid pump with compressed gas motive fluid |
US5849736A (en) | 1993-11-24 | 1998-12-15 | The Dupont Merck Pharmaceutical Company | Isoxazoline and isoxazole fibrinogen receptor antagonists |
WO1995032965A1 (fr) | 1994-06-01 | 1995-12-07 | Yamanouchi Pharmaceutical Co. Ltd. | Derive de l'oxadiazole et composition medicinale a base de ce dernier |
IL115420A0 (en) | 1994-09-26 | 1995-12-31 | Zeneca Ltd | Aminoheterocyclic derivatives |
US5719144A (en) | 1995-02-22 | 1998-02-17 | Merck & Co., Inc. | Fibrinogen receptor antagonists |
IL117805A0 (en) | 1995-04-07 | 1996-08-04 | Schering Corp | Carbonyl piperazinyl and piperidinyl compounds |
ZA963391B (en) | 1995-05-24 | 1997-10-29 | Du Pont Merck Pharma | Isoxazoline fibrinogen receptor antagonists. |
US5726126A (en) | 1995-06-02 | 1998-03-10 | American Cyanamid Company | 1-(3-heterocyclyphenyl)-S-triazine-2,6,6-oxo or thiotrione herbicidal agents |
US5741819A (en) | 1995-06-07 | 1998-04-21 | 3-Dimensional Pharmaceuticals, Inc. | Arylsulfonylaminobenzene derivatives and the use thereof as factor Xa inhibitors |
GB9516709D0 (en) | 1995-08-15 | 1995-10-18 | Zeneca Ltd | Medicament |
DE19536783A1 (de) | 1995-09-21 | 1997-03-27 | Diagnostikforschung Inst | Bifunktionelle Nicotinamid-Chelatbildner vom Typ N¶2¶S¶2¶ für radioaktive Isotope |
US5852045A (en) | 1995-10-19 | 1998-12-22 | Merck & Co., Inc. | Fibrinogen receptor antagonists |
US6274715B1 (en) | 1995-11-08 | 2001-08-14 | Abbott Laboratories | Tricyclic erythromycin derivatives |
GB9602294D0 (en) | 1996-02-05 | 1996-04-03 | Zeneca Ltd | Heterocyclic compounds |
ATE269312T1 (de) | 1996-04-17 | 2004-07-15 | Bristol Myers Squibb Pharma Co | N-(amidinophenyl)-n'-(subst.)-3h-2,4- benzodiazepin-3-on derivative als faktor xa inhibitoren |
US5668159A (en) | 1996-05-08 | 1997-09-16 | The Dupont Merck Pharmaceutical Company | 1,3,4-thiadiazoles and 1,3,4-oxadiazoles as IIb/IIIa antagonists |
AU3701797A (en) | 1996-08-14 | 1998-03-06 | Zeneca Limited | Substituted pyrimidine derivatives and their pharmaceutical use |
UA56197C2 (uk) | 1996-11-08 | 2003-05-15 | Зенека Лімітед | Гетероциклічні похідні |
US6440972B1 (en) | 1997-02-13 | 2002-08-27 | Zeneca Limited | Heterocyclic compounds useful as oxido-squalene cyclase inhibitors |
IT1291823B1 (it) | 1997-04-08 | 1999-01-21 | Menarini Ricerche Spa | Composti pseudo-peptidici, loro preparazione ed uso in formulazioni farmaceutiche |
DE69835430T2 (de) | 1997-05-30 | 2007-03-08 | Takeda Pharmaceutical Co. Ltd. | Sulfonamidderivate, ihre herstellung und verwendung |
US6207679B1 (en) * | 1997-06-19 | 2001-03-27 | Sepracor, Inc. | Antimicrobial agents uses and compositions related thereto |
CA2295153A1 (en) | 1997-06-26 | 1999-01-07 | Gerald Floyd Smith | Antithrombotic agents |
AU8270698A (en) | 1997-06-26 | 1999-01-19 | Eli Lilly And Company | Antithrombotic agents |
AU8270898A (en) | 1997-06-26 | 1999-01-19 | Eli Lilly And Company | Antithrombotic agents |
GB9715894D0 (en) | 1997-07-29 | 1997-10-01 | Zeneca Ltd | Heterocyclic derivatives |
GB9715895D0 (en) | 1997-07-29 | 1997-10-01 | Zeneca Ltd | Heterocyclic compounds |
ID23991A (id) | 1997-09-30 | 2000-06-14 | Daiichi Seiyaku Co | Turunan-turunan sulfonil |
AR013693A1 (es) | 1997-10-23 | 2001-01-10 | Uriach & Cia Sa J | Nuevas piperidinas y piperazinas como inhibidores de la agregacion plaquetaria |
US6130349A (en) * | 1997-12-19 | 2000-10-10 | The Board Of Trustees Of The Leland Stanford Junior University | Catalytic compositions and methods for asymmetric allylic alkylation |
EP0937723A1 (de) | 1998-02-18 | 1999-08-25 | Roche Diagnostics GmbH | Neue Sulfonamide, Verfahren zu ihrer Herstellung sowie diese enthaltende Arzneimittel |
EP0937711A1 (de) | 1998-02-18 | 1999-08-25 | Roche Diagnostics GmbH | Neue Thiobenzamide, Verfahren zu ihrer Herstellung sowie diese enthaltende Arzneimittel |
GB9807104D0 (en) | 1998-04-02 | 1998-06-03 | Chirotech Technology Ltd | The preparation of phosphine ligands |
DE19814801A1 (de) | 1998-04-02 | 1999-10-07 | Basf Ag | Verfahren zur Herstellung von 1,3,4-trisubstituierten 1,2,4-Triazoliumsalzen |
KR20010042868A (ko) * | 1998-04-21 | 2001-05-25 | 블레어 큐. 퍼거슨 | 항암제 및 증식 억제제로서의5-아미노인데노[1,2-c]피라졸-4-온 |
GB9809350D0 (en) | 1998-05-02 | 1998-07-01 | Zeneca Ltd | Novel salt |
GB9809349D0 (en) | 1998-05-02 | 1998-07-01 | Zeneca Ltd | Heterocyclic derivatives |
CA2331042A1 (en) | 1998-05-02 | 1999-11-11 | Astrazeneca Ab | Heterocyclic derivatives which inhibit factor xa |
CA2329770A1 (en) | 1998-06-30 | 2000-01-06 | Ian Campbell Lennon | The preparation of arylphosphines |
JP2000086659A (ja) | 1998-07-14 | 2000-03-28 | Takeda Chem Ind Ltd | オクタヒドロピリド[1,2―a]ピラジン誘導体 |
TW434207B (en) | 1998-07-24 | 2001-05-16 | Everlight Chem Ind Corp | Chiral ligand and method for preparing cyanohydrins from aldehydes |
US6303625B1 (en) | 1998-07-27 | 2001-10-16 | Ortho-Mcneil Pharmaceutical, Inc. | Triazolopyridines for the treatment of thrombosis disorders |
US6747023B1 (en) | 1998-08-11 | 2004-06-08 | Daiichi Pharmaceutical Co., Ltd. | Sulfonyl derivatives |
ES2196917T3 (es) | 1998-12-23 | 2003-12-16 | Lilly Co Eli | Amidas heteroaromaticas como inhibidores del factor xa`. |
DE69931393T2 (de) | 1998-12-23 | 2007-03-29 | Eli Lilly And Co., Indianapolis | Antithrombotische amide |
ATE272633T1 (de) | 1998-12-23 | 2004-08-15 | Lilly Co Eli | Aromatische amiden |
US6660739B1 (en) | 1998-12-24 | 2003-12-09 | Eli Lilly And Company | Heterocyclic amides as inhibitors of factor Xa |
GB9902989D0 (en) | 1999-02-11 | 1999-03-31 | Zeneca Ltd | Heterocyclic derivatives |
AU2241400A (en) * | 1999-04-06 | 2000-10-12 | Yamanouchi Pharmaceutical Co., Ltd. | Novel thiazolobenzoimidazole derivative |
JP4390024B2 (ja) | 1999-04-23 | 2009-12-24 | アステラス製薬株式会社 | 新規なジアゼパン誘導体又はその塩 |
GB9909592D0 (en) | 1999-04-26 | 1999-06-23 | Chirotech Technology Ltd | Process for the preparation of calanolide precursors |
JP2003500391A (ja) | 1999-05-24 | 2003-01-07 | シーオーアール セラピューティクス インコーポレイテッド | Xa因子阻害剤 |
US6855715B1 (en) | 1999-06-14 | 2005-02-15 | Eli Lilly And Company | Serine protease inhibitors |
EP1185488A1 (fr) * | 1999-06-15 | 2002-03-13 | Rhodia Chimie | Sulfonylamides et carboxamides et leur application en catalyse asymetrique |
GB9914342D0 (en) | 1999-06-19 | 1999-08-18 | Zeneca Ltd | Compound |
JP2001011071A (ja) | 1999-06-25 | 2001-01-16 | Mochida Pharmaceut Co Ltd | アミノアルキルスルホンアミド誘導体 |
US6492408B1 (en) * | 1999-07-21 | 2002-12-10 | Boehringer Ingelheim Pharmaceuticals, Inc. | Small molecules useful in the treatment of inflammatory disease |
GB9917344D0 (en) | 1999-07-24 | 1999-09-22 | Zeneca Ltd | Novel salt |
JP2003509409A (ja) | 1999-09-13 | 2003-03-11 | 3−ディメンショナル ファーマシューティカルズ, インコーポレイテッド | アザシクロアルカノンセリンプロテアーゼ阻害剤 |
EP1216231A2 (en) | 1999-09-17 | 2002-06-26 | Millennium Pharmaceuticals, Inc. | INHIBITORS OF FACTOR Xa |
KR100760434B1 (ko) | 1999-09-17 | 2007-10-04 | 밀레니엄 파머슈티컬스 인코퍼레이티드 | 벤즈아미드 및 관련된 Xa 인자의 억제제 |
EP1235807A1 (en) | 1999-11-24 | 2002-09-04 | Millennium Pharmaceuticals, Inc. | B-amino acid-, aspartic acid- and diaminopropionic-based inhibitors of factor xa |
WO2001064642A2 (en) | 2000-02-29 | 2001-09-07 | Cor Therapeutics, Inc. | Benzamides and related inhibitors of factor xa |
TWI290136B (en) * | 2000-04-05 | 2007-11-21 | Daiichi Seiyaku Co | Ethylenediamine derivatives |
AU2001275857A1 (en) | 2000-06-29 | 2002-01-14 | Bristol-Myers Squibb Pharma Company | Thrombin or factor xa inhibitors |
WO2002026734A1 (en) | 2000-09-29 | 2002-04-04 | Cor Therapeutics, Inc. | PIPERAZIN-2-ONE AMIDES AS INHIBITORS OF FACTOR Xa |
US20040082786A1 (en) | 2000-09-29 | 2004-04-29 | Bing-Yan Zhu | Piperazine based inhibitors of factor xa |
AU2002214626A1 (en) | 2000-09-29 | 2002-04-08 | Cor Therapeutics, Inc. | Quaternary amines and related inhibitors of factor xa |
US6710058B2 (en) | 2000-11-06 | 2004-03-23 | Bristol-Myers Squibb Pharma Company | Monocyclic or bicyclic carbocycles and heterocycles as factor Xa inhibitors |
US7504417B2 (en) | 2000-11-22 | 2009-03-17 | Astellas Pharma Inc. | Substituted benzene derivatives or salts thereof |
WO2002060859A2 (en) | 2000-12-20 | 2002-08-08 | Bristol-Myers Squibb Company | Cyclic derivatives as modulators of chemokine receptor activity |
DE60221505D1 (de) | 2001-03-30 | 2007-09-13 | Millennium Pharm Inc | FAKTOR Xa BENZAMIDIN INHIBITOREN |
US7365205B2 (en) | 2001-06-20 | 2008-04-29 | Daiichi Sankyo Company, Limited | Diamine derivatives |
PL220739B1 (pl) * | 2001-06-20 | 2015-12-31 | Daiichi Sankyo Company | Pochodne diaminy |
KR100908966B1 (ko) | 2001-08-09 | 2009-07-22 | 다이이찌 세이야꾸 가부시기가이샤 | 디아민 유도체 |
EP1427415B1 (en) | 2001-09-21 | 2009-08-12 | Brystol-Myers Squibb Company | Lactam-containing compounds and derivatives thereof as factor xa inhibitors |
US7030141B2 (en) | 2001-11-29 | 2006-04-18 | Christopher Franklin Bigge | Inhibitors of factor Xa and other serine proteases involved in the coagulation cascade |
WO2003048081A2 (en) | 2001-12-04 | 2003-06-12 | Bristol-Myers Squibb Company | Glycinamides as factor xa inhibitors |
EP1505966A4 (en) | 2002-05-10 | 2006-08-30 | Bristol Myers Squibb Co | 1,1-DISUBSTITUTED CYCLOALKYL DERIVATIVES AS FACTOR XA HEMMER |
US20070129371A1 (en) * | 2002-12-24 | 2007-06-07 | Daiichi Pharmaceutical Co., Ltd. | Novel ethylenediamine derivatives |
JP4109288B2 (ja) * | 2002-12-25 | 2008-07-02 | 第一三共株式会社 | ジアミン誘導体 |
-
2002
- 2002-03-20 US US10/481,262 patent/US7365205B2/en active Active
- 2002-03-20 WO PCT/JP2002/002683 patent/WO2003000657A1/ja active Application Filing
- 2002-06-19 MY MYPI20022307A patent/MY153231A/en unknown
- 2002-06-20 AR ARP020102322A patent/AR036102A1/es active IP Right Grant
- 2002-06-20 EP EP11002212A patent/EP2343290A1/en not_active Withdrawn
- 2002-06-20 TW TW091113510A patent/TWI298066B/zh active
- 2002-06-20 PT PT02743653T patent/PT1405852E/pt unknown
-
2003
- 2003-12-19 ZA ZA2003/09866A patent/ZA200309866B/en unknown
-
2004
- 2004-02-09 US US10/773,344 patent/US7342014B2/en not_active Expired - Lifetime
-
2007
- 2007-09-06 US US11/850,788 patent/US20080015215A1/en not_active Abandoned
-
2008
- 2008-12-30 US US12/259,496 patent/US20100093785A1/en not_active Abandoned
-
2009
- 2009-03-06 US US12/399,702 patent/US20090270446A1/en not_active Abandoned
-
2010
- 2010-05-21 US US12/784,710 patent/US20110077266A1/en not_active Abandoned
- 2010-12-13 US US12/966,640 patent/US20110312990A1/en not_active Abandoned
-
2012
- 2012-08-20 CY CY20121100742T patent/CY1113054T1/el unknown
-
2015
- 2015-07-16 BE BE2015C046C patent/BE2015C046I2/fr unknown
- 2015-08-20 CY CY2015034C patent/CY2015034I1/el unknown
- 2015-09-29 NL NL300760C patent/NL300760I2/en unknown
- 2015-10-09 FR FR15C0068C patent/FR15C0068I2/fr active Active
Also Published As
Publication number | Publication date |
---|---|
US20110312990A1 (en) | 2011-12-22 |
US20100093785A1 (en) | 2010-04-15 |
MY153231A (en) | 2015-01-29 |
US20090270446A1 (en) | 2009-10-29 |
BE2015C046I2 (enEXAMPLES) | 2021-07-19 |
WO2003000657A1 (fr) | 2003-01-03 |
CY1113054T1 (el) | 2016-04-13 |
FR15C0068I2 (fr) | 2016-04-22 |
FR15C0068I1 (enEXAMPLES) | 2015-12-04 |
US7342014B2 (en) | 2008-03-11 |
HK1092461A1 (en) | 2007-02-09 |
US20050020645A1 (en) | 2005-01-27 |
US20080015215A1 (en) | 2008-01-17 |
ZA200309866B (en) | 2005-03-30 |
AR036102A1 (es) | 2004-08-11 |
CY2015034I2 (el) | 2016-04-13 |
EP2343290A1 (en) | 2011-07-13 |
CY2015034I1 (el) | 2016-04-13 |
TWI298066B (en) | 2008-06-21 |
US7365205B2 (en) | 2008-04-29 |
US20050119486A1 (en) | 2005-06-02 |
PT1405852E (pt) | 2012-10-30 |
US20110077266A1 (en) | 2011-03-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NL300760I2 (en) | Edoxaban, a salt thereof, a solvate thereof or an N-oxide thereof, in particular edoxaban tosylate | |
NO2015022I2 (no) | Edoksaban, et salt derav, et solvat derav eller et N-oksid derav, spesielt edoksabantosilat | |
NL300996I1 (nl) | Naldemedine dan wel een farmaceutisch aanvaardbaar zout of solvaat daarvan, in het bijzonder het tosylaatzout | |
NL301020I2 (nl) | Avatrombopag, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout daarvan, in het bijzonder avatrombopag-maleaat | |
NL300913I2 (nl) | Cariprazine, optioneel in de vorm van een zout, waaronder cariprazine hydrochloride | |
FR17C1012I2 (fr) | 2-(pyridin-2-ylamino)-pyrido [2,3-d]pyrimidin-7-ones | |
DK1611131T3 (da) | Pyrazolopyridin-derivater | |
NO20054220D0 (no) | Substituerte N-arylheterocykler, fremgangsmate for fremstilling derav og deres anvendelse som legemiddel | |
DE602004026205D1 (de) | Roboterhand | |
NL1031976A1 (nl) | N-(pyridine-2-yl)sulfonamidederivativen. | |
EP1668781A4 (en) | CELLULAR BOOSTER WITH SHORT RANGE | |
DE112004001751D2 (de) | Socke | |
ATE394659T1 (de) | Probenhomogenisator | |
DE112004002437D2 (de) | Socke | |
ITMO20030289A1 (it) | Apparati, metodo e articolo. | |
DK1667668T3 (da) | Alfabeta3 og altabeta6-integrinantagonister som antifibrotiske midler | |
DK3184275T3 (da) | Polymere artikler | |
NL1033403A1 (nl) | Therapeutische pyrazolo[3,4-b]pyridinen en indazolen. | |
DE602004032218D1 (de) | Kontaktpunkteinrichtung | |
NL300918I1 (nl) | Naltrexon of een farmaceutisch aanvaardbaar zout daarvan, in het bijzonder naltrexonhydrochloride, en bupropion of een farmaceutisch aanvaardbaar zout daarvan, in het bijzonder bupropionhydrochloride | |
NO20053805D0 (no) | Diarylmetylindenpiperidinderivater, framgangsmate for fremstilling derav, og anvendelse derav | |
ITMO20030004A0 (it) | Macchina utensile. | |
ITMI20031132A0 (it) | Attrezzo da palestra perfezionato | |
FI20031240L (fi) | Hissin tarraajajärjestely | |
DE60316540D1 (de) | Brotbackgerät |